Case Report
Korean J Hematol 2009; 44(4):
Published online December 30, 2009
https://doi.org/10.5045/kjh.2009.44.4.315
© The Korean Society of Hematology
동종조혈모세포 이식 후 발생한 거대세포바이러스 폐렴에서 Ganciclovir와 Leflunomide 병합치료 경험 1예
임재희 이윤나 유양선 김한조 김경하 김세형 김현정 이상철 배상병 김찬규 이규택 박성규 원종호 홍대식 박희숙 박재성 이유경
순천향대학교 의과대학 종양혈액내과학교실, 영상의학교실, 진단검사의학교실
Ganciclovir and Leflunomide Combination Therapy for a Patient with Cytomegalovirus Pneumonia after Unrelated Allogenic Stem Cell Transplantation
Cytomegalovirus (CMV) infection is an important cause of morbidity and mortality among transplant recipients. The first line standard therapy for CMV pneumonia is treatment with a combination of ganciclovir and immunoglobulin. Nevertheless, the mortality of CMV pneumonia is 30∼70%. Leflunomide has been recently reported to have novel anti-CMV activity by inhibiting viron assembly. It is also cheaper and is more easily given orally as compared to ganciclovir. We report here on an allogenic stem cell transplant recipient who developed CMV pneumonia that was refractory to ganciclovir and immunoglobulin. The patient was successfully treated with a combination of leflunomide and ganciclovir. (Korean J Hematol 2009;44:315-319.)
Keywords Cytomegalovirus, Ganciclovir, Leflunomide
PDF
Standard view
Export citation
Share Article
Case Report
Korean J Hematol 2009; 44(4): 315-319
Published online December 30, 2009 https://doi.org/10.5045/kjh.2009.44.4.315
Copyright © The Korean Society of Hematology.
동종조혈모세포 이식 후 발생한 거대세포바이러스 폐렴에서 Ganciclovir와 Leflunomide 병합치료 경험 1예
임재희 이윤나 유양선 김한조 김경하 김세형 김현정 이상철 배상병 김찬규 이규택 박성규 원종호 홍대식 박희숙 박재성 이유경
순천향대학교 의과대학 종양혈액내과학교실, 영상의학교실, 진단검사의학교실
Ganciclovir and Leflunomide Combination Therapy for a Patient with Cytomegalovirus Pneumonia after Unrelated Allogenic Stem Cell Transplantation
Jae Hee Lim, Yun Nah Lee, Yang Seon Ryu, Han Jo Kim, Kyoung Ha Kim, Se Hyung Kim, Hyun Jung Kim, Sang Chul Lee, Sang Byung Bae, Chan Kyu Kim, Kyu Taek Lee, Seong Kyu Park, Jong Ho Won, Dae Sik Hong, Hee Sook Park, Jae Seong Park, You Kyoung Lee
Departments of Hematology-Oncology, Radiology and Laboratory Medicine, Soonchunhyang University School of Medicine, Bucheon, Korea
Abstract
Cytomegalovirus (CMV) infection is an important cause of morbidity and mortality among transplant recipients. The first line standard therapy for CMV pneumonia is treatment with a combination of ganciclovir and immunoglobulin. Nevertheless, the mortality of CMV pneumonia is 30∼70%. Leflunomide has been recently reported to have novel anti-CMV activity by inhibiting viron assembly. It is also cheaper and is more easily given orally as compared to ganciclovir. We report here on an allogenic stem cell transplant recipient who developed CMV pneumonia that was refractory to ganciclovir and immunoglobulin. The patient was successfully treated with a combination of leflunomide and ganciclovir. (Korean J Hematol 2009;44:315-319.)
Keywords: Cytomegalovirus, Ganciclovir, Leflunomide
Previous Article
Article Tools
Stats or Metrics
Share this article on
Related articles in BR
-
Clinical characteristics and treatment courses for cytomegalovirus-associated thrombocytopenia in immunocompetent children after neonatal period
Min Ji Jin, Yunkyum Kim, Eun Mi Choi, Ye Jee Shim, Heung Sik Kim, Jin Kyung Suh, Ji Yoon Kim, Kun Soo Lee, Sun Young Park, Jae Min Lee, and Jeong Ok Hah
Blood Res 2018; 53(2): 110-116 -
Clinical and radiologic evaluation of cytomegalovirus-induced thrombocytopenia in infants between 1 and 6 months of age
Joon-Won Kang, Gee-Na Kim, Sun-Young Kim, Hee-Jin Kim, Eun-Sil Park, Jae-Young Kim, and Young-Ho Lee
Korean J Hematol 2010; 45(1): 29-35 -
The Effect of Preemptive Therapy with Intravenous Ganciclovir Followed by Oral Ganciclovir against Cytomegalovirus Infection after Allogeneic Peripheral Blood Stem Cell Transplantation
Jong Gwang Kim, Woo Jin Sung, Yi Soo Che, Kwang Woon Seo, Sung Won Park, Jin Tae Jung, Sang Kyun Sohn, Jang Soo Suh, Kyu Bo Lee
Korean J Hematol 2002; 37(1): 31-37
